
A single lot of a common blood pressure drug was pulled nationwide after a risk of stainless-steel contamination surfaced—and the identifiers are precise enough for every patient to check fast.
Story Snapshot
- One lot of propranolol extended-release 60 mg was recalled nationwide at the consumer level.
- Exact identifiers: NDC 51991-817-01, lot PK25110035, expires May 2029.
- Risk involves possible austenitic stainless-steel particles; laceration hazard listed.
- Distribution ran October 26 to November 4, 2026, to wholesalers and pharmacies.
What Was Recalled And Why It Matters
Breckenridge Pharmaceutical issued a voluntary nationwide recall of one lot of propranolol hydrochloride extended-release capsules, 60 milligrams, sold in 100-count bottles. The recall targets lot PK25110035, National Drug Code 51991-817-01, with an expiration date of May 2029. The company urged consumers to stop using capsules from that lot and call their doctor for advice and replacement steps. State pharmacy regulators reported the suspected contaminant as austenitic stainless steel, which can harm soft tissue if swallowed.
Officials stated the lot went to market after October 26 and before November 4, 2026, and was shipped to wholesalers and pharmacies across the United States. The recall does not cover other strengths, other lots, or other brands. The safety warning describes a specific risk: small metal fragments could cut the mouth, throat, stomach, or intestines if present. That is why the stop-use instruction is blunt and immediate for anyone holding this exact bottle and lot.
How The Risk Was Detected
Regulators explained that the recalled lot shared the same intermediate material as a different lot in which metal contamination was observed; that other lot never reached the market. This is the playbook for sound drug quality control. When an intermediate shows a credible hazard, companies must trace every lot that touched it and act fast. The Food and Drug Administration’s guidance for active ingredients tells firms to assign clear recall rules, decision rights, and documentation so action is quick and thorough.
That is how a recall can be both narrow and urgent. Narrow, because it lists one lot with crystal-clear identifiers. Urgent, because foreign metal in oral drugs is a no-go at any size. While news headlines often say “blood pressure drug recalled,” the scope here is sharply limited to a single lot, one strength, in one bottle size. Patients on propranolol who do not have lot PK25110035 should stay on therapy and ask their pharmacist if unsure.
What Patients And Pharmacies Should Do Now
Patients who hold the listed lot should stop using it and call their doctor or pharmacist. Bring the bottle to the pharmacy so staff can verify the National Drug Code, lot, and expiration date. Pharmacies should pull stock, check returns, and contact wholesalers. Breckenridge’s notice directs consumers to seek replacement instructions and medical advice. Anyone with symptoms like mouth cuts, throat pain, stomach pain, or blood in stool should seek care right away and mention the recall when describing the medication history.
💊 BLOOD PRESSURE MEDICATION RECALLED NATIONWIDE OVER POSSIBLE METAL CONTAMINATION
Breckenridge Pharmaceutical Inc. issued a voluntary nationwide recall for one lot of 60 mg propranolol hydrochloride extended-release capsules (lot PK25110035, expiring May 2029) over potential…
— Erik Hoffmann (@TheErikHoffmann) November 17, 2026
Doctors and pharmacists should remind patients that propranolol is a beta blocker used for blood pressure and other conditions. Stopping the drug without a plan can cause harm. The right step is a safe swap to an unaffected lot or an equivalent product. That protects against both the recall risk and blood pressure rebound. This is common sense drug safety: verify the bottle, switch the lot if needed, and keep the core therapy steady.
Why A Precautionary Recall Still Makes Sense
Some readers ask why a lot is recalled if no bottle has yet been proven to contain metal. The answer lies in how reliable drug makers prevent harm, not react to it. Good manufacturing practice urges removal when credible cross-lot risk exists, even before a marketed unit tests positive. The Food and Drug Administration has logged many recalls for foreign material across products, including injectables and saline, underscoring that proactive recalls are routine quality hygiene, not panic.
This case checks the right boxes for transparency and traceability. The company named the lot, strength, National Drug Code, and expiration date. Regulators named the suspected material and explained the link through a shared intermediate. News outlets reported the nationwide scope and the tight distribution window. That clarity helps patients and pharmacies move quickly, avoid confusion, and keep treatment on track.
Sources:
foxbusiness.com, prnewswire.com, bnd.com, fda.gov






























